Stock Mountie

Daily Canadian Stock Market Information

Archive for the month “January, 2012”

31 Jan 2012

Posted in Uncategorized | Leave a Comment
31 Jan 2012

Berkwood Provides Update on Geological Mapping and Soil Sampling Results on the Cimandiri Gold Project

Berkwood Provides Update on Geological Mapping and Soil Sampling Results on the Cimandiri Gold Project

 

 

 

VANCOUVER, British Columbia, Jan. 31, 2012 /PRNewswire/ — Berkwood Resources Ltd. (TSX-V SYMBOL: BKR) (“Berkwood”) is pleased to provide an update on its 100% owned Cimandiri Gold Project in West Java, Indonesia and the previously reported geological mapping program utilising two mapping teams (see news release dated October 27th 2011), as well as an update on the continuing soil sampling program taking place on the Cimandiri Property.

Geological mapping of alteration, structure and lithology has now been completed. Surface geological mapping and geochemical analysis of the samples have identified two gold targets, the Cipetir prospect and the Cisaru prospect (see map here). These prospect areas indicate a low sulphidation epithermal system associated with stockwork style mineralization.

The surface and soil sampling program, that continues on the property, has confirmed the Cipetir and Cisaru prospects, which were previously identified during geological mapping. Soil and rock sampling has also confirmed the continuity of mineralization and alteration between the Cipetir and Cisaru gold prospects (see maps here).

This sampling has also identified a new prospect, the Lubang prospect, a 500 m2 area of interest on the Cimandiri property, where an old, hand dug adit made by locals with a depth of 2 meters was found. A grab sample in the adit has returned a result of 5.4 g/ton, and soil sampling has confirmed this anomaly on surface. The Lubang prospect is still open to the North West and North East.

The soil samples have been taken at depths between 1 to 6 meters, following ridge and spur sampling technique. Hand auger tools are being utilized to reach the ‘C’ horizon level. As sampling continues, infill sampling will take place between the areas of interest to expand all of the current prospects.

Soil and rock samples are being sent to Intertek laboratories in Jakarta for geochemical analysis of Au, Ag, Cu, Pb, Zn, Hg, and As using Fire Assay, Acid Assay, and ICP.

Johannes Erasmus, associate geologist of Micromine Pty Ltd, a Qualified Person as defined by National Instrument 43-101, reviewed and approved the content of this News Release.

About Berkwood Resources

 

Berkwood now holds a 100% interest in the Prospect Valley Gold Property near Merritt, BC.  To date, several areas of gold mineralization have been identified on the 107 km2 property.  The majority of historic drilling has taken place in the centre of the claim block along a prominent north-northeast trending linear zone.  This drilling outlined NI43-101 compliant Mineral Resources totaling 166,000 ounces grading 0.511 g/t gold, 10,077,000 metric tonnes above a cut-off of 0.30g/t gold (see news release dated January 25th 2012)  at the combined Discovery South and Discovery North Zones. The zones remain open for expansion and other known zones of gold mineralization have yet to be drilled.

Berkwood has a 100% interest in the Cimandiri Gold Property in Indonesia, located 120km south of Jakarta, approximately 3 hours driving time.  Railway lines are nearby, with the closest rail station located only 8km from the property.  The project is located 9km southwest of the Cikondang Gold mine.  Berkwood has carried out initial mapping and geochemical sampling during the first phase of exploration and will continue to report material results as they are received.

If you are not currently on the Berkwood Resources updates list, please visit our website by clicking here to opt-in to the list: http://www.berkwoodresources.com/contact.html. The Company will send out regular updates and news releases to everyone who asks to be on the list.

For additional information please contact:

Karim Sayani, Corporate Communications Tel: (604) 662-7455 begin_of_the_skype_highlighting            (604) 662-7455     end_of_the_skype_highlighting E-mail: karim@berkwoodresources.com

Tom Steer, Media Relations Manager Tel: (604) 681-5556 begin_of_the_skype_highlighting            (604) 681-5556     end_of_the_skype_highlighting E-mail: tomsteer@berkwoodresources.com

On Behalf of Berkwood Resources, Brian Buchanan, President and Director

This Berkwood News Release contains certain “forward-looking” statements and information relating to Berkwood that are based on the beliefs of Berkwood’s management as well as assumptions made by and information currently available to Berkwood’s management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors and strategic partners, the interest rate environment, governmental regulation and supervision, seasonality, technological change, changes in industry practices, and one-time events. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results and forward-looking statements may vary materially from those described herein. Berkwood does not assume the obligation to update any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

Posted in Uncategorized | Leave a Comment
31 Jan 2012

Plains Creek announces the appointment of Kirill Zimin to its board of directors

VANCOUVER ,  Jan. 31, 2012  /CNW/ – Further to its news release dated  January 17, 2012  with respect to the closing of the first tranche (the “First Tranche“) of its brokered private placement raising gross proceeds of  $1,625,000 , which is part of a larger offering (the “Offering“) anticipated to raise a total of  $3,250,000 , Plains Creek Phosphate Corporation (“Plains Creek“, the “Company“) (TSX-V: PCP.V – News) is pleased to announce the appointment of  Mr. Kirill Zimin  to the board of directors of the Company.  In connection with the strategic investment of Tabac Ventures Limited (“Tabac“) pursuant to the Offering, Tabac was granted the right to appoint a nominee to the board of the Company.   Mr. Zimin  is the nominee of Tabac.

Tabac is a company affiliated with Aterra Capital, an investment fund which is currently being established by Alexey Mordashov.

Mr. Zimin  joined Aterra Capital in 2011 as a partner of the management company of the fund. Before that he used to work as an independent M&A adviser in the junior mining sector and as Head of Business Development in  Africa  for Severstal Resources, a division of OAO Severstal.   Mr. Zimin  graduated from  Moscow  State University with a law degree, has previously held directorships of multiple mining companies and has extensive experience in business development and corporate governance.

The Company looks forward to working with  Mr. Zimin  to achieve the Company’s strategic objectives.

NI 43-101 Compliant Technical Report:

The Company’s current technical report (the “Technical Report“) for its Farim Phosphate Project prepared in accordance with National Instrument 43-101 (“NI 43-101“) is entitled, “Technical Report on the Preliminary Economic Assessment of the Farim Phosphate Project,  Guinea-Bissau ” dated effective  February 10, 2010 , and was filed under the Company’s profile on SEDAR at www.sedar.com on  February 22 , 2011.  The Technical Report was prepared for the Company by John S. Warwick, B.Sc. (Hons) PIMMM, C.Eng., Eur.Ing. (Mining) of IMC Group Consulting Limited;  Andre Lambert , B.Sc., MIMMM, EurGeol of IMC Group Consulting Limited;  Alex Mitchell , MIMMM, C.Eng. of GBM Minerals Engineering Consultants Limited; and  Michael Short , FIMMM, C.Eng. of GBM Minerals Engineering Consultants Limited, all of whom are independent Qualified Persons as defined under NI 43-101.

About Plains Creek Phosphate Corporation:

Plains Creek Phosphate Corporation is a Canadian mining and exploration company focused on advancing its Farim Phosphate Project located in  Guinea-Bissau , West Africa.  The Project consists of a high-quality development phosphate deposit containing a NI 43-101 compliant measured phosphate resource of 69 million tonnes (“Mt“) grading 29.9% P2O5, an indicated resource of  15 Mt  grading 30.1% P2O5, and an inferred resource of 44 Mt grading 29.6% P2O5.  The Project has a 25 year mining plan of 68 Mt phosphate grading 29.9% P2O5, as disclosed in the Company’s NI 43-101 compliant Technical Report.  The Company is currently undertaking a Definitive Feasibility Study and has been granted a Production License from the Government of  Guinea-Bissau  to pursue a strategy towards phosphate rock production of  2 Mt  per annum for a minimum of 25 years, starting in 2014.  Based on the Technical Report, estimated costs before contingency include capital costs of US$288 million and operating costs of US$60 per tonne.  The Company’s shares are listed on the TSX Venture Exchange under the trading symbol “PCP”.  For additional information, please visit us at www.plainscreek.com.

ON BEHALF OF THE BOARD

(signed) “ Carson Phillips “ Carson Phillips Vice-President, Corporate Development and Director

Cautionary Statement

Statements in this release may be viewed as forward-looking statements. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. There are no assurances the Company can fulfill such forward-statements and the Company undertakes no obligation to update statements. Such forward looking statements are only predictions; actual events or results may differ materially as a result of risks facing the Company, some of which are beyond the Company’s control.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Posted in Uncategorized | Leave a Comment
30 Jan 2012

Medisafe 1 Technologies Advancing Negotiations to Acquire Additional Lifesaving Medical Technologies

Medisafe 1 Technologies Corp. (OTCBB: MFTH.OB – News), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company is expanding efforts to acquire companies with commercial-stage technologies that augment its existing commercial product line.

Business development efforts are underway to acquire companies with medical devices and / or lifesaving technologies that are already revenue generating.

“Medisafe 1 Technologies continues its efforts to become a leading developer of lifesaving medical technology,” said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. “We are now in the market for companies that have already proven an ability to generate revenues with medical technologies. These technologies will compliment Medisafe 1 Technologies’ patented syringe locking device and transfusion bag locking device that have already proven to be commercially-viable.”

About Medisafe 1 Technologies Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle.  Medisafe’s patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.
Forward-Looking Statements This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated.  Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

 

Posted in Uncategorized | Leave a Comment
27 Jan 2012

ASTC – 1st Detect Announces the Delivery of Pre-Production Mini-Mass Spectrometers to Select Customers

AUSTIN, Texas, Jan. 26, 2012 (GLOBE NEWSWIRE) — 1st Detect Corporation, a subsidiary of Astrotech Corporation (Nasdaq:ASTC – News), is pleased to announce the delivery of pre-production mini-mass spectrometers to select customers for evaluation.

“After years of development, we are very proud to have leading analytical equipment vendors evaluating our mini-mass spectrometer,” said Thomas B. Pickens III, Chairman of 1st Detect. “We believe 1st Detect’s mini-mass spectrometer technology represents a breakthrough by delivering performance comparable to large laboratory mass spectrometers in a small and affordable instrument that can reach many applications that were never before possible. This is a major development milestone as 1st Detect is now transforming from its R&D phase to a market driven, commercially focused business enterprise.”

The 1st Detect mini-mass spectrometer technology is capable of detecting trace levels of volatile compounds and has been developed for the security, industrial and research laboratory markets. We believe the technology platform is ideally suited for these applications, having been designed to provide highly accurate and rapid analysis and detection of very low concentrations of chemical compounds.

“I am extremely excited about the technology breakthroughs the 1st Detect team has innovated,” added Mr. Pickens. “Our talented R&D team has spent years developing what we consider to be the best performing miniature mass spectrometer available. This product fulfills an unmet need in the chemical detection market by providing a true mini-mass spectrometer that is superior to the widely adopted ion mobility spectrometry (IMS) products.”

The 1st Detect proprietary mini-mass spectrometry technology provides a broad and versatile platform that we plan to integrate with follow-on products optimized for the security and industrial markets including airports, border crossings, law enforcement, military uses, agricultural processing, refineries, chemical plants, pharmaceutical manufacturing, process control, water and wastewater treatment facilities.

About 1st Detect Corporation

1st Detect Corporation was formed by Astrotech Corporation (Nasdaq:ASTC – News) to develop and commercialize miniature-mass spectrometer technology first developed under an agreement with NASA for use on the International Space Station (ISS). 1st Detect offers what we believe is a breakthrough mini-mass spectrometry technology that fills an unmet need by being highly accurate, rapid, lightweight, durable and cost-effective. For more information on 1st Detect Corporation, please visit www.1stDetect.com.

About Astrotech Corporation

Astrotech is one of the first space commerce companies and remains a strong entrepreneurial force in the aerospace industry. We are leaders in identifying, developing and marketing space technology for commercial use. Our ASO business unit serves our government and commercial satellite and spacecraft customers with pre-launch services on the eastern and western range. 1st Detect Corporation is developing what we believe is a breakthrough mini-mass spectrometer, while Astrogenetix, Inc. is a biotechnology company utilizing microgravity as a research platform for drug discovery and development.

The 1st Detect Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7997

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, the ability to expand ASO, the availability of capital for reinvestment in growth initiatives, the continued development of technology solutions, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

Posted in Uncategorized | Leave a Comment
26 Jan 2012

Golden Hope Intersects 6140 g/t Au (197.4 oz/t Au) of Gold Over 1 Metre at Bellechasse-Timmins, Quebec

MONTREAL, Jan. 26, 2012 /CNW/ - Golden Hope Mines (TSX VENTURE: GNH)(Pink Sheets: GOLHF)- Golden Hope Mines Limited is pleased to announce further assay results from its Summer/Fall 2011 Drill Campaign in South-eastern, Quebec. The company received results from 3 holes including BD2011-165, 166 and 167.

Result highlights are presented in the table below.

Hole Number From (m) To (m) Length (m) Au (g/t)
BD2011-166 260 385 125 0.52
Including 353 385 32 1.29
BD2011-167 282 335 53 0.63
Including 282 297 15 1.50
Including 329 335 6 1.25
BD2011-167 374 380 6 1024
Including 374 375 1 1.87
Including 375 376 1 6140
Including 376 380 4 0.59

The lengths are core length and the assays are uncut.

Hole BD2011-167 was drilled to test a possible extension of the T1 Zone at depth to the northeast.  The hole intersected a 40% quartz-filled breccia with coarse visible gold from 370m to 377m in the core at a vertical depth of 270m.  The section between 374m and 380m returned above background gold values including 1 metre that gave a preliminary assay of 6140 g/t Au (50g gold Fire Assay with gravimetric finish).

The gold assay was confirmed by total pulp metallic treatment of the entire reject from the preliminary assay.  0.414kg of reject returned 6060 g/t Au and 0.997 kg of reject returned 6890 g/t Au.

A photo of the core from this intersection was previously reported in the November 18, 2011 press release and can be viewed at http://cnw.ca/6EnWg

“We are extremely pleased with these latest results. As we continue our aggressive drill campaign, we keep encountering significant mineralization. We are working to define the area around Bellechasse-Timmins and these results combined with the previous results in the 2011 campaign, provide us with the motivation to push forward enthusiastically. Results such as those encountered in hole 167 are certainly very encouraging and need to be interpreted within the context of the entire deposit” states Frank Candido, President, Golden Hope Mines Limited.

Following the exceptional visuals on hole BD2011-167, SGS recommended two wedges, holes BD2011-167A and BD2011-167B with the objective of defining the orientation of the brecciated zone. Samples from the wedges have been shipped to the SGS Mineral Services laboratory in Toronto for assaying.

Hole BD2011-165 was drilled to confirm the closing of the T1 Zone to the south west near surface and did not intersect significant gold values.

Samples were prepared and analyzed at SGS Minerals Services of Toronto, Ontario (Don Mills laboratory). Analysis for gold was done on one half of core samples following FAI525 fire assay procedure .

Golden Hope drilled 27 holes or approximately 12000 metres at Bellechasse-Timmins in 2011. Including the holes reported above, the company has 16 of 27 holes from the 2011 campaign which remain outstanding at Bellechasse-Timmins..

Since January 4, 2012, Golden Hope has currently drilled 3 holes or approximately 1000 metres at Bellechasse-Timmins as part of the Winter 2012 Drill Campaign. The company expects to be drilling throughout the winter. All outstanding drill results will be reported when they are received and interpreted.

Claude Duplessis, P.Eng and Claude Bisaillon, P.Eng. are acting as independent qualified persons (QP) for Golden Hope in compliance with National Instrument 43-101 and have reviewed the technical contents of this press release.

James E. Tilsley, P.Eng is acting as the qualified person (QP) for Golden Hope in compliance with National Instrument 43-101 and has reviewed the technical contents of this release.

Forward-Looking Information:

This news release contains certain forward-looking information as defined in applicable securities laws (referred to herein as “forward-looking statements”). Specifically, this news release contains forward-looking statements regarding the drill results being incremental to current potential. Forward-looking statements involve known and unknown risks, uncertainties and other factors which are beyond Golden Hope’s ability to predict or control and may cause Golden Hope’s actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. Golden Hope undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein whether as a result of new information or future events or otherwise, except as may be required by law.

About Golden Hope Mines Limited:

Golden Hope Mines Limited is a mineral exploration company that seeks to grow shareholder value through the acquisition, exploration and development of potentially large-scale gold and base metal projects suitable for underground and/or open-pit mining. The company’s focus is in southeastern Quebec, Canada. The company’s claim blocks lie within an area that extends approximately 100 kilometres along the Appalachians of southern Quebec from near Ste-Lucie-de-Beauregard to about 16 kilometres southwest of Beauceville. The Bellechasse-Timmins gold deposit lies 5 kilometres southeast of St-Magloire within the Bellechasse Belt an approximately 18 kilometre long mineralized area. The Bellechasse-Timmins gold deposit includes the T1, T2A, T2B, Ascot/Road gold zones, and eight known parallel gold-bearing breccias in the adjoining 88 Diorite. The company is also working to develop other targets within its claim blocks including the FSG gold and base metal target, the St-Luc (Roux) target, Chute du Bras, the LG showing, Moose Cliff, and Talon. For further information on Golden Hope Mines Limited please visit http://www.goldenhopemines.com.

Image with caption: “Visible gold in hole BD2011-167 at 375-376m. NQ core. (CNW Group/Golden Hope Mines Limited)”. Image available at:  http://photos.newswire.ca/images/download/20120126_C6973_PHOTO_EN_9247.jpg

          Contacts

Golden Hope Mines Limited
 Frank Candido
: President   Director
 514-750-8218 begin_of_the_skype_highlighting            514-750-8218     end_of_the_skype_highlighting
416-864-0175 begin_of_the_skype_highlighting            416-864-0175     end_of_the_skype_highlighting (FAX) fcandido@goldenhopemines.com info@goldenhopemines.com
www.goldenhopemines.com

Investor Relations USA:
American Capital Ventures Richard Hull:
305-918-7000 begin_of_the_skype_highlighting            305-918-7000     end_of_the_skype_highlighting

Posted in Uncategorized | Leave a Comment
26 Jan 2012

Rosetta Genomics Ltd. (ROSG)

Company Overview
<!–Company Overview –>Introduction

Rosetta Genomics is a leading developer of microRNA-based diagnostic tests and therapeutic tools. MicroRNAs (miRNAs) are a recently discovered group of short (21–23 nucleotides in length), non-coding genes which regulate the expression of other genes. MicroRNAs have also been shown to have varying expression levels across various pathological conditions, and offer a new class of highly sensitive and tissue specific biomarkers. MicroRNA-based diagnostics may offer physicians and patients an objective tool to accurately identify cancer, predict outcomes and help guide treatment.

Platform Technologies

Backed by a strong IP portfolio, Rosetta Genomics’ scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, women’s health and other indications.

Development Engine

Based on our strong IP position which provides us access to hundreds of potential microRNAs biomarkers, our proprietary technologies, and our extensive network of collaborations, Rosetta Genomics has put in place a powerful development engine which can rapidly advance a wide range of microRNA-based tests.

Advancing Cutting Edge Molecular Diagnostics

Rosetta Genomics’ proprietary technologies enable the development of a wide range of diagnostic tests for cancer and women’s health indications. Rosetta genomics believes that utilizing microRNAs as biomarkers in the development of next generation molecular diagnostics, presents several advantages over other currently used methods:

  • While many currently available cancer tests are largely qualitative and subjective, measuring microRNA expression levels in tissue samples offers quantitative, objective diagnosis.
  • Rosetta Genomics’ proprietary technologies enable microRNAs to be profiled with high sensitivity and specificity.
  • MicroRNAs are stable markers in many body fluids and tissue samples, making them an ideal platform for molecular diagnostics.
  • MicroRNAs have been found to be stable in Formalin Fixed Paraffin Embedded (FFPE) samples. FFPE samples, which are kept at room temperature, are the most widely used method for preserving tumor tissue. This will allow physicians to send samples for microRNA profiling via regular mail, without the need for temperature control.

MicroRNA-based Therapeutics

We seek to establish relationships with leading pharmaceutical companies and research institutions to develop microRNA-based products. In 2006, we joined forces with Isis Pharmaceuticals Inc. to develop a drug for liver cancer. We have identified several microRNA targets, that, when inhibited, lead to a decrease in liver cancer cell growth in in vivo studies1.

About the Rosetta Stone

Rosetta Genomics takes its name from the Rosetta Stone, a large ancient stone engraving discovered by Napoleon’s troops in 1799 in a small village on the Nile Delta. The Rosetta Stone includes sections of carved text presented in three different ancient scripts, including ancient Egyptian Hieroglyphics. For the first time, thanks to the Rosetta Stone, researchers were able to decipher ancient Egyptian Hieroglyphics, thereby opening the Ancient World to modern eyes. As the Rosetta Stone helped to decode the meaning of ancient texts, so Rosetta Genomics is dedicated to unlocking the mysteries of microRNA, and more generally of the genetic code. We believe our efforts will help many others to understand this new “language” in healthcare and introduce a new generation of diagnostic and therapeutic products to improve human health
Posted in Uncategorized | Leave a Comment
25 Jan 2012

THQ Outlines Business Strategy of Focusing Exclusively on High-Quality Core Games and Connected Experiences for Key Franchises

AGOURA HILLS, Calif.–(BUSINESS WIRE)–      THQ       Inc. (NASDAQ: THQI – News) announced its updated business strategy as the       company exits traditional kids’ licensed video games and focuses on its       core video game franchises and digital initiatives for the future. The       company will continue to build its strong portfolio of core game       franchises and align its resources to deliver games on both existing       consoles and new and emerging platforms. The company intends to       accelerate digital revenues by extending and supporting key console       launches, and to create dedicated digital properties for emerging       platforms.

As part of the alignment, THQ is in the process of exiting its       relationships with kids’ licensed entertainment companies but will       continue to sell certain previously released titles.

“THQ will be a more streamlined organization focused only on our       strongest franchises,” said Brian Farrell, President and CEO, THQ. “The       success of Saints Row®: The Third™ is an example of what our       revised strategy and focus can achieve. We have now shipped 3.8 million       units globally and are currently expecting to ship between five and six       million units lifetime on this title. Additionally, our robust digital       content offerings for this game have resulted in the highest digital       revenue of any console title in our history.”

The company’s five internal studios are developing games aligned to       several of THQ’s key franchises, including the upcoming launch of       UFC® Undisputed™ 3 and Darksiders® II, as well as Company       of Heroes, inSANE, Saints Row, Warhammer 40,000, and the new title       from Patrice Désilets and his team. The company also continues to work       with prominent external development talent on both existing and new       franchises. THQ’s goal is to optimize its portfolio for the current       generation of consoles and to establish new franchises on the next       generation of game devices.

THQ will discuss its new streamlined business model that reflects this       strategy in more detail on its third quarter 2012 conference call       scheduled for Thursday, February 2, 2012.

About THQ

THQ       Inc. (NASDAQ: THQI – News) is a leading worldwide developer and publisher       of interactive entertainment software. The company develops its products       for all popular game systems, personal computers, wireless devices and       the Internet. Headquartered in Los Angeles County, California, THQ sells       product through its global network of offices located throughout North       America, Europe and Asia Pacific. More information about THQ and its       products may be found at http://www.thq.com/.       THQ and the THQ logo are trademarks and/or registered trademarks of THQ       Inc.

THQ Inc. Caution Concerning Forward-Looking Statements

This press release contains statements that are forward-looking       statements within the meaning of the Private Securities Litigation       Reform Act of 1995. These forward-looking statements are based on       current expectations, estimates and projections about the business of       THQ Inc. and its subsidiaries (collectively referred to as “THQ”),       including, but not limited to, expectations of video game console and       software growth, financial guidance, estimated release dates and the       potential for online gaming. These statements are based upon       management’s current beliefs and certain assumptions made by management.       Such forward-looking statements are subject to risks and uncertainties       that could cause actual results to differ materially from those       expressed or implied by such forward-looking statements, including, but       not limited to, business, competitive, economic, legal, political and       technological factors affecting our industry, operations, markets,       products or pricing. Readers should carefully review the risk factors       and the information that could materially affect THQ’s financial       results, described in other documents that THQ files from time to time       with the Securities and Exchange Commission, including its Annual Report       on Form 10-K for the fiscal period ended March 31, 2011 and subsequent       Quarterly Reports on Form 10-Q, and particularly the discussion of       trends and risk factors set forth therein. Unless otherwise required by       law, THQ disclaims any obligation to update its view on any such risks       or uncertainties or to revise or publicly release the results of any       revision to these forward-looking statements. Readers are cautioned not       to place undue reliance on these forward-looking statements, which speak       only as of the date of this press release.

 

Contact:
Angela Emery THQ Corporate Communications 818/871-8650 or Lisa Mueller THQ Investor Relations 818/871-5125
Posted in Uncategorized | Leave a Comment
24 Jan 2012

ECOLAND INTL INC (ECIT.OB)

D&R is Awarded Contract to Manufacture and Develop Tooling for New 2012 Toyota Vehicle

 

CHANDLER, Ariz., Jan. 24, 2012 (GLOBE NEWSWIRE) — D & R Technology Inc., a wholly owned subsidiary of Ecoland International, Inc. (OTCBB:ECIT.OB – News), one of North America’s fastest growing applied-robotics companies, announced today the receipt of a tooling contract from Toyota Boshoku (Pink Sheets:TDBOF), a major tier one automotive parts supplier.

D&R has been awarded a contract to manufacture and develop tooling for a new 2012 Toyota vehicle. As an addition to the previously released retrofit, this new contract is confirmation of the strongly developed partnership between Toyota Boshoku and D & R Technology.

“We are determined to secure proffered status with all major automotive suppliers. Achieving that status with Toyota Boshoku is part of our global presence plan. Understanding needs and successfully executing projects for the three most demanding markets (North-American, Asian and European), accompanied with new product line developments, is the vital part of that plan. Recently announced contracts show our extraordinary ability to partner with companies from any part of the world with entirely different manufacturing philosophies,” stated Drasko Karanovic (President and CEO of D & R Technology):

About Toyota Boshoku America, Inc.

Toyota Boshoku Corporation is based in Kariya City, Japan, with 88 operations in more than 20 countries. Its wholly owned subsidiary, Toyota Boshoku America (TBA) and its affiliates employ about 6,500 team members in 23 locations throughout the United States, Canada, Mexico and Argentina. TBA is a premier manufacturer of automotive interior systems which include seats, door trims, headliners and substrates, carpets, fabrics and straps, in addition to air and oil filters for a variety of customers such as Toyota Motor Corporation and General Motors. For more information, visit www.toyota-boshoku.co.jp/en/.

About D & R Technology Inc.

www.dnrtechnology.com

D & R Technology designs, manufactures, and markets industrial and consumer products. Through independent subsidiaries we provide state of the art automation technology solutions to enable customers to dramatically accelerate time-to-market and increase revenue.

D & R Technology Inc. is a recognized technology pioneer and market leader in the area of engineering, design and the manufacturing of automated tube processing solutions for the automotive industry. It is emerging as one of the world’s leading providers of automated manufacturing solutions, which are used by three of the top ten automotive part suppliers in the world.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the future anticipated direction of the Company, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth, potential contracts, and/or aspects of litigation. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of, Ecoland International Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions. Persons are encouraged to read our Annual Report on Form 10-K for the year ended May 31, 2011 and our other documents subsequently filed with the Securities and Exchange Commission for meaningful cautionary language in respect of forward-looking statements in this press release. Interested persons are able to obtain free copies of filings containing information about the Company at the SEC’s internet site (http://www.sec.gov). The Company assumes no obligation to update any of these forward-looking statements.

 

Contact:
Ecoland International, Inc. Drasko Karanovic drasko@dnrtechnology.com www.dnrtechnology.com
Posted in Uncategorized | Leave a Comment
24 Jan 2012

LTS NUTRACEUTICALS (LTSN.OB)

University Study Confirms LTS Nutraceuticals’ BioCalth® Product Repairs Bone Deterioration More Effectively than Other Calcium Products in the Marketplace

FT. LAUDERDALE, Fla.–(BUSINESS WIRE)–      LTS Nutraceuticals, Inc. (the “Company”) (OTCBB: LTSN.OB – News), a developer and       manufacturer of nutritional and personal care products, today announced       that a clinical study was done on BioCalth® product that confirmed       BioCalth’s effectiveness in repairing bone deterioration. The study was       conducted by Dr. Jing Liang MD PhD, Associate Professor of Molecular &       Medical Pharmacology at the David Geffen School of Medicine, UCLA. Dr.       Liang has over 20 years of experience in pharmaceutical research and       development.

BioCalth® is a unique, patented Calcium L-Threonate supplement that was       clinically tested to determine whether BioCalth could improve bone       density and encourage the formulation of cartilage and collagen to       strengthen bones.* Osteogenesis is the formation and development of       bone. Bone is a dynamic tissue that is constantly being reshaped by       osteoblasts, in charge of production of osteoid matrix and their       mineralization. Osteoblast cells tend to decrease with age, affecting       the balance of formation and absorption in the bone tissue, often       causing bone fractures.

Dr. Liang and her team determined that BioCalth not only increased       osteoblast numbers and enhanced mineralization of osteoids; BioCalth       also was absorbed by the osteoblasts five times more than other calcium       products that were compared to. Study also showed that BioCalth       increased osteoid collagen and made alkaline phosphatase activated which       is in charge of transforming osteoid into mineralized or calcified       extracellular matrix or new bone tissue.

“We continue to study the effects of BioCalth, as the product could       potentially benefit over 40 million Americans that have an increased       risk of bone fracture,” commented Dr. Liang. “We believe that BioCalth       can be a candidate for therapeutic medication for Osteoporosis,       Osteogenesis Imperfecta and other disease induced problems, bone mass       loss or pain due to bone mass loss and even supplementary treatment       after teeth-implants.”

“BioCalth is only now being introduced to the U.S. market and we believe       with this research, the products’ effectiveness, compared to other       leading brands of calcium products, has been validated and we can expect       to see a demand for BioCalth products throughout the retail channels,”       commented CEO of LTS Nutraceuticals, Jerry Rayman.

*These products have not been evaluated by the FDA and are not intended       to diagnose, treat, cure, or prevent any disease.

About LTS Nutraceuticals, Inc.

Headquartered in Ft. Lauderdale, FL, LTS Nutraceuticals, Inc. develops,       manufactures, markets and distributes an expanding line of unique,       high-quality vitamins, vitamin boosters, dietary supplements and       nutraceuticals. The products are sold throughout North America through       two marketing channels: direct selling utilizing Inline Marketing™ to       introduce products to the consumer and marketing products through       national retail, drug and grocery chains and club stores.

More information about the Company, visit: www.LTSNinc.com

Forward-Looking Statements

This release contains forward-looking statements within the meaning of       the Private Securities Litigation Reform Act of 1995. Statements       contained in this release that are not historical facts, including,       without limitation,statements that relate to the Company’s expectations       with regard to the future impact on the Company’s results from new       products in development, may be deemed to be forward-looking statements.       Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”,       “anticipates”, “likely”, “believes” and words of similar import also       identify forward-looking statements. These statements are subject to       risks and uncertainties. Forward-looking statements are based on current       facts and analyses and other information that are based on forecasts of       future results, estimates of amounts not yet determined and assumptions       of management. Readers are urged not to place undue reliance on the       forward-looking statements, which speak only as of the date of this       release. Except as may be required under applicable law, we assume no       obligation to update any forward-looking statements in order to reflect       any event or circumstance that may arise after the date of this release.       Additional information on risks and other factors that may affect the       business and financial results of LTS Nutraceuticals, Inc. can be found       in the filings of LTS Nutraceuticals, Inc. with the U.S. Securities and       Exchange Commission

Posted in Uncategorized | Leave a Comment

Post Navigation

← Older Entries
Follow

Get every new post delivered to your Inbox.